- Report
- October 2023
- 172 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- February 2024
- 110 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- January 2024
- 200 Pages
Global
From €4012EUR$4,150USD£3,448GBP
- Report
- September 2020
- 700 Pages
Global
From €4737EUR$4,900USD£4,071GBP
- Report
- March 2020
- 293 Pages
Global
From €4736EUR$4,899USD£4,071GBP
- Report
- August 2022
- 198 Pages
Global
From €5317EUR$5,500USD£4,570GBP
- Report
- April 2023
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- April 2023
- 120 Pages
Global
From €4592EUR$4,750USD£3,947GBP
- Report
- February 2018
- 302 Pages
Global
From €3915EUR$4,050USD£3,365GBP
- Book
- June 2018
- 368 Pages
- Book
- January 2018
- 176 Pages
- Book
- January 2018
- 272 Pages
- Book
- February 2016
- 1416 Pages
- Book
- September 2010
- 418 Pages
The Human Pluripotent Stem Cell (hPSC) market is a subset of the larger stem cell market. hPSCs are derived from human embryos and are capable of developing into any type of cell in the body. They are used in research and drug development, as well as in regenerative medicine. hPSCs are also used to create disease models, which can be used to study the underlying mechanisms of diseases and to develop new treatments.
The hPSC market is growing rapidly, driven by advances in technology and increasing demand for stem cell-based therapies. The market is expected to continue to grow in the coming years, as more applications for hPSCs are developed.
Some of the major players in the hPSC market include Cellular Dynamics International, Pluristem Therapeutics, Stem Cell Technologies, and Thermo Fisher Scientific. Show Less Read more
